Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin for extensive disease small cell lung cancer
Not Applicable
- Conditions
- Extensive disease small cell lung cancer
- Registration Number
- JPRN-UMIN000002615
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1. With serirous comprications such as infection, heart disease, lung fibrosis. 2. With symptomatic brain metastasis or massive effusion 3. With active other malignancies 4. Pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method